Vigabatrin

Anti-epileptic Agent — NERVOUS SYSTEM

Key facts

Vigabatrin is an ofp drug in the Anti-epileptic Agent class catalogued in DrugCentral. It was first approved by the FDA in 2009. DrugCentral lists 3 molecular targets, including Abat, Abat and ABAT. Recorded indications include Epilepsy characterized by intractable complex partial seizures and West syndrome.

• Approval status: ofp (first approved 2009 by the FDA).
• Drug class: Anti-epileptic Agent.
• Molecular targets: Abat, Abat and ABAT (3 listed in DrugCentral).
• Indications: Epilepsy characterized by intractable complex partial seizures and West syndrome.
• ATC code: N03AG04 (Fatty acid derivatives).
• Molecular formula: C6H11NO2; molecular weight 129.16 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Epilepsy characterized by intractable complex partial seizures
• West syndrome

Contraindications (11)

• Anemia
• Breastfeeding (mother)
• Edema
• Kidney disease
• Mood swings
• Peripheral nerve disease
• Pregnancy, function
• Reduced visual acuity
• Suicidal thoughts
• Visual field defect
• Weight gain finding

Mechanism & targets

• Established pharmacologic class: Anti-epileptic Agent

Molecular targets (3)

Target	Gene	Action	Activity
4-aminobutyrate aminotransferase, mitochondrial	Abat	unknown	IC50 4.40
Gamma-amino-N-butyrate transaminase	Abat	unknown	IC50 4.38
4-aminobutyrate aminotransferase, mitochondrial	ABAT	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2009-08-21	FDA	—	LUNDBECK LLC

ATC classification

ATC code	Therapeutic hierarchy
N03AG04	NERVOUS SYSTEM › ANTIEPILEPTICS › ANTIEPILEPTICS › Fatty acid derivatives

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Seizure	4194.0
Magnetic resonance imaging head abnormal	1412.6
Drug withdrawal convulsions	1345.9
Retinogram abnormal	833.1
Status epilepticus	677.8
Drug ineffective	660.9
Product dose omission issue	633.7
Multiple-drug resistance	549.5
Visual field defect	399.6
Death	392.5
Somnolence	362.6
Infantile spasms	345.2

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Vigabatrin is on its molecule page.

• Molecular formula: C₆H₁₁NO₂
• Molecular weight: 129.16 g/mol
• CAS number: 68506-86-5
• InChIKey: PJDFLNIOAUIZSL-UHFFFAOYSA-N
• PubChem CID: 5665

NC(CCC(O)=O)C=C

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Vigabatrin used for?

DrugCentral lists the following indications for Vigabatrin: Epilepsy characterized by intractable complex partial seizures and West syndrome.

How does Vigabatrin work?

Its molecular targets in DrugCentral include Abat, Abat and ABAT (inhibitor).

When was Vigabatrin first approved?

Vigabatrin was first approved by the FDA in 2009.

What drug class does Vigabatrin belong to?

Vigabatrin is in the Anti-epileptic Agent class.

What is the chemical formula of Vigabatrin?

Vigabatrin has the molecular formula C6H11NO2 and a molecular weight of 129.16 g/mol.

Sources

• DrugCentral drug card 2819 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL89598 — compound record and bioactivity
• PubChem CID 5665 — chemical identifiers
• DrugBank DB01080 — drug record
• FDA UNII GR120KRT6K — substance identity
• DailyMed: FDA labels for Vigabatrin — current prescribing information (label search)
• UniProt P80404 (ABAT) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.